Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH
Dual modulation of FXR and HSD17B13 presents a promising strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). Compound <b>6</b>, a groundbreaking dual modulator of FXR and HSD17B13, validates the concept of significantly enhancing liver function, reducing inflammation and fibrosis across various MAFLD models.
Authors
- Zhiming Yan (ORCID: https://orcid.org/0009-0001-2030-9203)
- Changhong Wei (ORCID: https://orcid.org/0000-0002-8852-3978)
- Jing Han (ORCID: https://orcid.org/0000-0001-5605-1868)
- Neng Jiang (ORCID: https://orcid.org/0000-0002-3261-8935)
- Yun Liu
Institutions
- Jiangsu Normal University (CN)
- Guangxi Medical University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- First People's Hospital of Nanning (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c00539
- Citations
- 6
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.13